197 related articles for article (PubMed ID: 24516518)
1. ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients.
Qi M; Yang X; Zhang F; Lin T; Sun X; Li Y; Yuan H; Ren Y; Zhang J; Qin X; Han B
PLoS One; 2014; 9(2):e84959. PubMed ID: 24516518
[TBL] [Abstract][Full Text] [Related]
2. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
Bismar TA; Yoshimoto M; Vollmer RT; Duan Q; Firszt M; Corcos J; Squire JA
BJU Int; 2011 Feb; 107(3):477-85. PubMed ID: 20590547
[TBL] [Abstract][Full Text] [Related]
3. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.
Han B; Mehra R; Lonigro RJ; Wang L; Suleman K; Menon A; Palanisamy N; Tomlins SA; Chinnaiyan AM; Shah RB
Mod Pathol; 2009 Aug; 22(8):1083-93. PubMed ID: 19407851
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.
Ateeq B; Kunju LP; Carskadon SL; Pandey SK; Singh G; Pradeep I; Tandon V; Singhai A; Goel A; Amit S; Agarwal A; Dinda AK; Seth A; Tsodikov A; Chinnaiyan AM; Palanisamy N
Prostate; 2015 Jul; 75(10):1051-62. PubMed ID: 25809148
[TBL] [Abstract][Full Text] [Related]
5. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.
Yoshimoto M; Joshua AM; Cunha IW; Coudry RA; Fonseca FP; Ludkovski O; Zielenska M; Soares FA; Squire JA
Mod Pathol; 2008 Dec; 21(12):1451-60. PubMed ID: 18500259
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.
Reid AH; Attard G; Ambroisine L; Fisher G; Kovacs G; Brewer D; Clark J; Flohr P; Edwards S; Berney DM; Foster CS; Fletcher A; Gerald WL; Møller H; Reuter VE; Scardino PT; Cuzick J; de Bono JS; Cooper CS;
Br J Cancer; 2010 Feb; 102(4):678-84. PubMed ID: 20104229
[TBL] [Abstract][Full Text] [Related]
7. The expression profile and heterogeneity analysis of ERG in 633 consecutive prostate cancers from a single center.
Nie L; Pan X; Zhang M; Yin X; Gong J; Chen X; Xu M; Zhou Q; Chen N
Prostate; 2019 Jun; 79(8):819-825. PubMed ID: 30900303
[TBL] [Abstract][Full Text] [Related]
8. Deletion of 8p is an independent prognostic parameter in prostate cancer.
Kluth M; Amschler NN; Galal R; Möller-Koop C; Barrow P; Tsourlakis MC; Jacobsen F; Hinsch A; Wittmer C; Steurer S; Krech T; Büscheck F; Clauditz TS; Beyer B; Wilczak W; Graefen M; Huland H; Minner S; Schlomm T; Sauter G; Simon R
Oncotarget; 2017 Jan; 8(1):379-392. PubMed ID: 27880722
[TBL] [Abstract][Full Text] [Related]
9. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer.
Bismar TA; Yoshimoto M; Duan Q; Liu S; Sircar K; Squire JA
Histopathology; 2012 Mar; 60(4):645-52. PubMed ID: 22260502
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T
BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067
[TBL] [Abstract][Full Text] [Related]
11. Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
Mehra R; Salami SS; Lonigro R; Bhalla R; Siddiqui J; Cao X; Spratt DE; Palapattu GS; Palanisamy N; Wei JT; Chinnaiyan AM; Tomlins SA
Med Oncol; 2018 Oct; 35(12):152. PubMed ID: 30291535
[TBL] [Abstract][Full Text] [Related]
12. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.
Gumuskaya B; Gurel B; Fedor H; Tan HL; Weier CA; Hicks JL; Haffner MC; Lotan TL; De Marzo AM
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):209-15. PubMed ID: 23545904
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic Significance of
Pan XY; Tan JY; Nie L; Yin XX; Gong J; Chen XQ; Zhou Q; Zeng H; Chen N
Sichuan Da Xue Xue Bao Yi Xue Ban; 2017 Jan; 48(1):66-70. PubMed ID: 28612561
[TBL] [Abstract][Full Text] [Related]
14. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.
Huang KC; Evans A; Donnelly B; Bismar TA
Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.
Cuzick J; Yang ZH; Fisher G; Tikishvili E; Stone S; Lanchbury JS; Camacho N; Merson S; Brewer D; Cooper CS; Clark J; Berney DM; Møller H; Scardino P; Sangale Z;
Br J Cancer; 2013 Jun; 108(12):2582-9. PubMed ID: 23695019
[TBL] [Abstract][Full Text] [Related]
16. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
17. Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone.
Liu S; Yoshimoto M; Trpkov K; Duan Q; Firszt M; Corcos J; Squire JA; Bismar TA
Cancer Biol Ther; 2011 Mar; 11(6):562-6. PubMed ID: 21178509
[TBL] [Abstract][Full Text] [Related]
18. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.
Steurer S; Mayer PS; Adam M; Krohn A; Koop C; Ospina-Klinck D; Tehrani AA; Simon R; Tennstedt P; Graefen M; Wittmer C; Brors B; Plass C; Korbel J; Weischenfeldt J; Sauter G; Huland H; Tsourlakis MC; Minner S; Schlomm T
Eur Urol; 2014 Dec; 66(6):978-81. PubMed ID: 25015038
[TBL] [Abstract][Full Text] [Related]
19. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade.
Yoshimoto M; Ding K; Sweet JM; Ludkovski O; Trottier G; Song KS; Joshua AM; Fleshner NE; Squire JA; Evans AJ
Mod Pathol; 2013 Mar; 26(3):435-47. PubMed ID: 23018874
[TBL] [Abstract][Full Text] [Related]
20. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J
Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
